Wyeth Tops The Wall Street Journal Patent Scorecard
The August 7, 2007, issue of The Wall Street Journal Patent Scorecard ranks Wyeth (Madison, NJ, www.wyeth.com) first among 35 global pharmaceutical companies evaluated for patent-based intellectual property (IP).
The August 7, 2007, issue of The Wall Street Journal Patent Scorecard ranks Wyeth (Madison, NJ, www.wyeth.com) first among 35 global pharmaceutical companies evaluated for patent-based intellectual property (IP). Pfizer, Inc. (New York, NY, www.pfizer.com) took the second position and Johnson & Johnson (New Brunswick, NJ, www.jnj.com) was ranked third, with Bristol-Myers Squib (New York, NY, www.bms.com) and Novartis AG (Basel, Switzerland, www.novartis.com) following close behind at numbers four and five.
The indicators used for measuring patent-based IP included patents granted; quality of patents; science strength, or the degree to which a company’s patent portfolio is linked to core science; research intensity, a comparative measure of the level of basic research; and innovation cycle time.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
